Selvita

Discovery CRO · Integrated drug discovery

Overview

Leading European drug-discovery CRO (spun out from the company that became Ryvu). Serves global biotech & pharma across chemistry and biology.

What they do

Selvita is one of Europe's leading drug-discovery contract research organizations (CROs), listed on the Warsaw Stock Exchange. It provides science-driven R&D services to global biotech and pharmaceutical clients, spanning integrated drug discovery, medicinal and computational chemistry, biology, preclinical studies and GLP/GMP-compliant analytical development, offered as either standalone or fully integrated programs.

Lead program & status

As a services company, Selvita's "pipeline" is its client and capability portfolio rather than proprietary drugs. It emerged from a 2019 corporate split of the original Selvita group: the proprietary oncology drug-discovery business became Ryvu Therapeutics, while the contract-research arm continued as the present-day Selvita. Since then it has scaled through organic growth and acquisitions, including Fidelta (2021) and, reportedly, PozLab (2024), broadening its in-vivo, ADMET and formulation capabilities. The group has also retained interests connected to precision-medicine/AI work (e.g., Ardigen). Through the 2020s it has positioned itself as an end-to-end early-discovery partner for international clients.

Why it matters

Selvita anchors Poland's position in the global drug-discovery value chain, giving worldwide biotechs access to high-quality, cost-competitive European discovery science and helping originate the chemistry behind novel therapeutics.

FAQ

How is Selvita related to Ryvu Therapeutics?

Both originated from the same group. In a 2019 corporate split, the proprietary oncology drug-discovery business became Ryvu Therapeutics, while the contract-research services arm continued as today's Selvita.

What services does Selvita offer?

Selvita is a drug-discovery CRO offering integrated and standalone services across medicinal and computational chemistry, biology, preclinical studies and GLP/GMP analytical development.

How has Selvita grown?

It has expanded organically and through acquisitions, including Fidelta in 2021 and, reportedly, PozLab in 2024, broadening its discovery and preclinical capabilities.

Company website / source ↗ Open the interactive map →